CN101244068A - Hemsleyadin sustained-release preparation - Google Patents
Hemsleyadin sustained-release preparation Download PDFInfo
- Publication number
- CN101244068A CN101244068A CNA2007100656773A CN200710065677A CN101244068A CN 101244068 A CN101244068 A CN 101244068A CN A2007100656773 A CNA2007100656773 A CN A2007100656773A CN 200710065677 A CN200710065677 A CN 200710065677A CN 101244068 A CN101244068 A CN 101244068A
- Authority
- CN
- China
- Prior art keywords
- hemsleyadin
- release
- sustained
- release preparation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003405 delayed action preparation Substances 0.000 title claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 229920003168 pharmaceutical polymer Polymers 0.000 claims description 7
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- -1 hydroxypropyl Chemical group 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 229930191394 Curcurbitacin Natural products 0.000 abstract 4
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 229940088710 antibiotic agent Drugs 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000000034 method Methods 0.000 description 10
- 239000006187 pill Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- VVBWBGOEAVGFTN-LPQIEKFGSA-N (2s,3s,8s,9r,10r,13r,14s,16r,17r)-17-[(2r)-2,6-dihydroxy-6-methyl-3-oxoheptan-2-yl]-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-11-one Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(O)C)C=C2[C@H]1C[C@H](O)[C@@H](O)C2(C)C VVBWBGOEAVGFTN-LPQIEKFGSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000219104 Cucurbitaceae Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001529246 Platymiscium Species 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- LKYNAQSYQLFTCM-GYXNDICUSA-N [(6r)-6-hydroxy-2-methyl-5-oxo-6-[(2s,3s,8s,9r,10r,13r,14s,16r,17r)-2,3,16-trihydroxy-4,4,9,13,14-pentamethyl-11-oxo-1,2,3,7,8,10,12,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl]heptan-2-yl] acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)[C@@H](O)C2(C)C LKYNAQSYQLFTCM-GYXNDICUSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- AQEGCOVXDRJSKR-UHFFFAOYSA-N cucurbitacin IIa Natural products CC(=O)OC(C)(C)CCC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(CC(O)C(O)C4(C)C)C3(C)CCC12C AQEGCOVXDRJSKR-UHFFFAOYSA-N 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a special form sustained-release preparation of natural antibiotics curcurbitacin, in particular to a membrane controlled or/and matrix release oral preparation with the composition as follows: curcurbitacin 5 to 20%, water insoluble medical macromolecular material 30 to 65%, water soluble medical macromolecular material 5 to 25%, and conventional auxiliary material 15 to 45%. The special form sustained-release preparation of natural antibiotics curcurbitacin has the advantages of retarding the release of curcurbitacin from drug preparation, reducing the peak and peak valley for drug absorption, facilitating stable plasma drug concentration, and especially facilitating the disease treatment when the sustained release is combined with rapid release since the rapid release part can be rapidly released to produce the plasma drug concentration required for treatment as soon as possible, while the sustained release part can subsequently provide stable plasma drug concentration and reduce the fluctuation of plasma drug concentration.
Description
Technical field
The present invention relates to a kind of slow releasing preparation of natural antibacterial medicine hemsleyadin of special form.
Background technology
Hemsleyadin is the hemsleyadin first (Cucurbitacin IIa) extracted in the Cucurbitaceae Radix Hemsleyae Macrospermae platymiscium and the mixture of hemsleyadin second (Cucurbitacin IIb).Pharmacological research shows that hemsleyadin has heat-clearing and toxic substances removing, antibacterial and anti-inflammation functions.Report that hemsleyadin all has antibacterial activity to gram positive bacteria and negative bacterium, hemsleyadin is＜0.00036～0.75mgml to the MIC of gram positive bacteria
-1MIC to gram negative bacteria is 0.0056～1.5mgml
-1Its intensity and chloromycetin are good natural antibacterial medicines quite or strong slightly.Other there are some researches show that hemsleyadin is about 2.5mgml to the minimal inhibitory concentration of influenza virus
-1, the prompting Radix Hemsleyae Macrospermae have the effect of resisiting influenza virus.Radix Hemsleyae Macrospermae have and suppresses the effect of mice caused by dimethylbenzene xylene ear swelling, can suppress the rabbit fervescence due to the endotoxin under heavy dose.Clinical practice for many years shows, hemsleyadin determined curative effect, toxic and side effects are little, the toleration of antibiotic-free.At present, there have two kinds of general formulations of hemsleyadine tablet and hemsleyadin capsule to be applied to be clinical, is mainly used in treatment bacillary dysentery, enteritis, bronchitis, acute tonsillitis, pulmonary tuberculosis, leprosy and urinary system infection etc.
Chinese patent CN1493296 (application number: 03159197.3) disclose a kind of " drop pills of hemsleyadin and preparation method thereof ", the hemsleyadin fine powder of 1 weight portion through micronizing is added in 1～10 weight portion molten matrix, abundant mixing, dropping preparation method is condensed into ball in coolant, remove coolant, drying, promptly.CN1872075 (application number: 200510013623.3) another kind of drop pills of hemsleyadin and preparation method thereof is then disclosed, it overcome the used adjuvant pure natural of present drop pill degree not high and at present the common chemical synthesis auxiliary material not in some national food additive catalogue, the relatively poor shortcoming of drop pill mouthfeel.
Keep stable blood drug level during the Drug therapy, reducing peak valley phenomenon is the important directions of oral formulations development.Existing 'Xuedansu ' need be taken 3 times common every day, takes inconvenience, and can not realize stable drug release.
Summary of the invention
Thereby the object of the present invention is to provide a kind of hemsleyadin that can delay from pharmaceutical preparation, to discharge the peak valley phenomenon that reduces drug absorption, help keeping the hemsleyadin sustained-release preparation of stable blood drug level.
The film control release type that hemsleyadin sustained-release preparation of the present invention is made up of following components in weight percentage is or/and the oral formulations of skeleton release type: hemsleyadin 5～20%, the medicinal macromolecular material 30～65% of water-insoluble, water solublity pharmaceutical polymers 5～25%, conventional adjuvant 15～45%.
Principal agent Radix Hemsleyae Macrospermae of the present invention have commercially available, it is the mixture of hemsleyadin first (Cucurbitacin IIa) and hemsleyadin second (CucurbitacinIIb), also available well-established law is by extracting in the Cucurbitaceae Radix Hemsleyae Macrospermae platymiscium, contain hemsleyadin in the hemsleyadin first, be not less than 95% (national drug standards WS3-B-36).
The medicinal macromolecular material of water-insoluble of the present invention can be the high viscosity hydroxypropyl emthylcellulose (＞100cps), in the medicinal macromolecular materials of water-insoluble such as cured, the polyvinyl acetate of methacrylic acid, high poly-degree Polyethylene Glycol (label is more than 800), sodium alginate, glyceryl monostearate, glyceryl tristearate, Petiolus Trachycarpi, polymethacrylates, ethyl cellulose, methyl methacrylate, polyvinylpyrrolidone one or two or more kinds.Even more preferably: hydroxypropyl emthylcellulose, ethyl cellulose, glyceryl monostearate, methyl methacrylate.
Water solublity pharmaceutical polymers of the present invention can be methylcellulose, hydroxypropyl cellulose, low-viscosity hydroxypropylmethylc,llulose (≤100cps), a kind of in the water solublity pharmaceutical polymers such as polyvinyl alcohol, oligomeric degree Polyethylene Glycol (label is below 400), polypropylene glycol, triethanolamine, sodium stearate, Stepanol MG or several.Even more preferably: hydroxypropyl cellulose, oligomeric degree Polyethylene Glycol, sodium stearate.
Conventional adjuvant of the present invention mainly is other pharmaceutic adjuvants such as lubricant and/or filler, can be starch, amylum pregelatinisatum, dextrin, lactose, microcrystalline Cellulose, calcium sulfate, medicinal calcium carbonate, magnesium stearate, micropowder silica gel, pigment etc.
The present invention is various oral formulations such as the tablet, capsule, pill of film control release type and skeleton release type.The slow releasing preparation of single dose hemsleyadin contains hemsleyadin 4～30mg.More excellent content range is 6～18mg.
The present invention has selected the medicinal macromolecular material of specific water-insoluble as skeleton, principal agent is dispersed to be evenly distributed in the sustained-release matrix, and regulate the speed that body fluid permeates in skeleton with specific water solublity pharmaceutical polymers, thereby from pharmaceutical preparation, discharge the peak valley phenomenon that reduces drug absorption thereby can delay hemsleyadin, help keeping stable blood drug level.When especially adopting the release pattern of rapid release+slow release, oral back immediate release section rapid release, help setting up as soon as possible the blood drug level that satisfies the treatment needs, slow-released part then can provide at follow-up time and keep comparatively stable blood concentration, reduce the fluctuation of blood drug level, more help treatment of diseases.
The release in vitro degree test experimental data of hemsleyadin sustained-release preparation of the present invention below is provided:
One, detects index and method
1. experimental condition: press Chinese Pharmacopoeia version appendix in 2005 XD drug release determination method first method, carry out rotating speed 50rpm, 37 ℃ ± 0.5 ℃ of temperature with reference to " changeing the basket method " in the dissolution test.Wherein 0～2h release medium is pH1.2 hydrochloric acid solution+0.05% tween 80 (medium I), 2～4h release medium is pH5.0 phosphate buffer+0.05% tween 80 (medium II), 4～8h release medium is pH6.8 phosphate buffer (medium III), and 8～12h release medium is pH7.4 phosphate buffer (medium IV).
2. test method
Precision takes by weighing in right amount (being equivalent to hemsleyadin 2mg approximately) and puts in the 50ml measuring bottle, adds the ethanol jolting and makes dissolving, adds ethanol dilution again to scale, shakes up, and filters, and makes reference substance solution.Get this product and put in the dissolution tester commentaries on classics basket, test by above-mentioned experimental condition.At the 2nd hour, the 4th hour, the 8th hour and the 12nd hour were respectively by drawing test solution among medium I～medium IV.It is an amount of that other gets the hemsleyadin reference substance, uses the medium dissolves identical with test solution and dilution, product solution in contrast.Get test solution and reference substance solution and measure trap at 273nm wavelength place, calculate the burst size of this product day part, add up successively, get final product the release profiles of this product.
Other gets commercially available hemsleyadine tablet and puts the dissolution tester and change in the basket, carries out the dissolution test in medium I, every sampling in 10 minutes 1 time, measures with method, and the burst size of day part adds up successively, get final product the release profiles of hemsleyadin conventional tablet.
Two, result of the test
See Fig. 1.
The result: the hemsleyadin sustained-release preparation that three embodiment of the present invention make carries out external pH gradient experiment under the intravital environment of simulation, change the medium of different pH value in the regular hour, detect the release in vitro degree of each preparation, the result shows, the hemsleyadin sustained-release preparation that three embodiment make all can realize slowly discharging medicine under the intravital environment of simulation.
Description of drawings
Fig. 1 is different prescriptions, method for making and the test of dosage form hemsleyadin sustained-release preparation release in vitro degree.
The specific embodiment
Quote embodiment below the present invention and further specify, but the embodiment that quotes of institute does not form restriction to covering scope of the present invention.
Embodiment 1:
Form:
Hemsleyadin 18g
Ethyl cellulose 36g
Stearic acid 54g
Hydroxypropyl cellulose 9g
Dextrin 22g
Micropowder silica gel 3.2g
Magnesium stearate 0.9g
Method for making: get stearic acid 54g, hydroxypropyl cellulose 6g, hemsleyadin 18g pulverizes, and crosses 100 mesh sieves, is dispersed in the ethyl acetate, volatilizes solvent.Pulverize, cross 80 mesh sieves.Other gets ethyl cellulose 36g, and hydroxypropyl cellulose 3g mixes the back and pulverizes, and crosses 80 mesh sieves, adds the dextrin 22g and the medicated powder that contains hemsleyadin of 80 mesh sieves, and mix homogeneously is used 95% alcohol granulation, drying, 40 mesh sieve granulate.Add micropowder silica gel 3.2g, magnesium stearate 0.9g mixes the back tabletting, makes every slow releasing tablet that contains hemsleyadin 18mg.
Embodiment 2:
Form:
The slow-released part immediate release section
Hemsleyadin 18g 6g
Hydroxypropyl emthylcellulose 50g
Polyethylene Glycol 1600 20g
Triethanolamine 6g
Sodium stearate 5g 30g
Lactose 50g
Microcrystalline Cellulose 18g
Medicinal calcium carbonate 10g
Magnesium stearate 0.7g 0.5g
Method for making:
1, slow-released part: get hydroxypropyl emthylcellulose 46g, Polyethylene Glycol 20g, triethanolamine 6g, sodium stearate 5g, hemsleyadin 18g fully mixes the back and pulverizes, and crosses 100 mesh sieves.Other gets propyl methocel 4g, uses an amount of ethanol, is mixed with 3% solution, granulates, and drying with 40 mesh sieve granulate, adds the 0.7g magnesium stearate, mix homogeneously.
2, immediate release section: get hemsleyadin 6g,, mix the back and pulverize, cross 100 mesh sieves, add microcrystalline Cellulose 6g, magnesium stearate 0.5g, mix homogeneously with sodium stearate 30g, lactose 50g, microcrystalline Cellulose 12g, medicinal calcium carbonate 10g.
3, tabletting: get the slow-released part for preparing and put in the label feeder of double-layer tablet tablet machine, immediate release section is put in the outer feeder of double-layer tablet tablet machine, sets up parameter, and making label and outer weight ratio is 1: 1.15.Suppress every double-layer sustained release tablets that contains hemsleyadin 24mg.
Embodiment 3:
Form:
The slow-released part immediate release section
Hemsleyadin 9g 3g
Methyl methacrylate 41.5g
Glyceryl monostearate 20g
PEG400 7g
Hydroxypropyl cellulose 2.2g
Micropowder silica gel 22g
Magnesium stearate 0.5g 0.3g
Lactose 22g
Dextrin 10g
Starch 5.5g
Method for making:
1, slow-release pill preparation:
Get hemsleyadin 9g, micropowder silica gel 22g mixes the back and pulverizes, and crosses 100 mesh sieves.Glyceryl monostearate 20g after 70～75 ℃ of heating and melting, adds the 35g methyl methacrylate, and the 7g PEG400 fully mixes, insulation.Add and contain hemsleyadin medicated powder, fully mix, and progressively reduce temperature, adjust mixing speed, when having granule to form, add magnesium stearate 0.5g, continue to stir, make the rounding piller of particle diameter 0.9～1.1mm, every 100Mg contains hemsleyadin 9mg.Put and use Opadry in the coating pan
The II coating, the weightening finish of control coating is 10%.
2, release pills preparation:
Get hemsleyadin 3g, lactose 22g, dextrin 15.5g; mix the back and pulverize, cross 80 mesh sieves, add hydroxypropyl cellulose 2.2g; make binding agent with 10% starch starch slurry, make the rounding piller of particle diameter 0.9～1.1mm in one-step-granulating method, every 100Mg contains hemsleyadin 7.5mg.Put and use Opadry in the coating pan
The II coating, the weightening finish of control coating is 10%.
3, filling capsule:
In slow-release pill: the ratio of release pills=5: 2, use metering disc type capsule filling machine or cannula type capsule filling machine through transforming, two kinds of pillers are loaded in the 2# hard capsule get final product.Every loading amount is 154mg, contains hemsleyadin 12mg.
Claims (6)
1. hemsleyadin sustained-release preparation, the film control release type that it is characterized in that being made up of following components in weight percentage is or/and the oral formulations of skeleton release type: hemsleyadin 5～20%, the medicinal macromolecular material 30～65% of water-insoluble, water solublity pharmaceutical polymers 5～25%, conventional adjuvant 15～45%.
2. hemsleyadin sustained-release preparation as claimed in claim 1 is characterized in that the medicinal macromolecular material of described water-insoluble is that high viscosity hydroxypropyl emthylcellulose, methacrylic acid, high poly-degree Polyethylene Glycol, sodium alginate, glyceryl monostearate, glyceryl tristearate, Petiolus Trachycarpi are cured, in the polyvinyl acetate, polymethacrylates, ethyl cellulose, methyl methacrylate, polyvinylpyrrolidone one or more.
3. hemsleyadin sustained-release preparation as claimed in claim 2, its feature described be in hydroxypropyl emthylcellulose, ethyl cellulose, glyceryl monostearate, the methyl methacrylate one or more in the medicinal macromolecular material of water-insoluble.
4. hemsleyadin sustained-release preparation as claimed in claim 1 is characterized in that described water solublity pharmaceutical polymers is one or more in methylcellulose, hydroxypropyl cellulose, low-viscosity hydroxypropylmethylc,llulose, polyvinyl alcohol, oligomeric degree Polyethylene Glycol, polypropylene glycol, triethanolamine, sodium stearate, the Stepanol MG.
5. hemsleyadin sustained-release preparation as claimed in claim 4 is characterized in that described water solublity pharmaceutical polymers is one or more in hydroxypropyl cellulose, oligomeric degree Polyethylene Glycol, the sodium stearate.
6. hemsleyadin sustained-release preparation as claimed in claim 1 is characterized in that described conventional adjuvant is lubricant and/or filler.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100656773A CN101244068B (en) | 2007-02-13 | 2007-02-13 | Hemsleyadin sustained-release preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100656773A CN101244068B (en) | 2007-02-13 | 2007-02-13 | Hemsleyadin sustained-release preparation |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101439997A Division CN101829121B (en) | 2007-02-13 | 2007-02-13 | Hemsleyadin sustained-release preparation |
| CN2010101427133A Division CN101780094B (en) | 2007-02-13 | 2007-02-13 | Slow-release preparation of cucurbitacin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101244068A true CN101244068A (en) | 2008-08-20 |
| CN101244068B CN101244068B (en) | 2010-09-29 |
Family
ID=39944890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100656773A Active CN101244068B (en) | 2007-02-13 | 2007-02-13 | Hemsleyadin sustained-release preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101244068B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979027A (en) * | 2010-10-29 | 2011-02-23 | 四川逢春制药有限公司 | Method for detecting Jinze coronary disease capsules |
| CN111411099A (en) * | 2020-05-14 | 2020-07-14 | 云南农业大学 | Snow bile acetyltransferase and its encoding gene and its application in the preparation of snow bile A |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872075B (en) * | 2005-06-01 | 2010-11-03 | 天津天士力制药股份有限公司 | Drop pills of hemsleyadin, and preparation method |
-
2007
- 2007-02-13 CN CN2007100656773A patent/CN101244068B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979027A (en) * | 2010-10-29 | 2011-02-23 | 四川逢春制药有限公司 | Method for detecting Jinze coronary disease capsules |
| CN111411099A (en) * | 2020-05-14 | 2020-07-14 | 云南农业大学 | Snow bile acetyltransferase and its encoding gene and its application in the preparation of snow bile A |
| CN111411099B (en) * | 2020-05-14 | 2022-09-27 | 云南农业大学 | Hemsleya amabilis acetyl transferase, coding gene thereof and application of hemsleya amabilis acetyl transferase in preparation of cucurbitacin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101244068B (en) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657629B (en) | Ticagrelor sustained-release tablet system and preparation method thereof | |
| CN102091051B (en) | Allopurinol dual-release preparation and preparation method thereof | |
| CN101416947A (en) | Compound alpha-ketoacid chewing tablet and preparation method | |
| CN102114005B (en) | Tracleer capsule and preparation method thereof | |
| CN100542528C (en) | Bicyclol Micronization and Oral Controlled Release Preparation | |
| CN103006594A (en) | Glimepiride composite and preparation method thereof | |
| CN102764254B (en) | A kind of levetiracetam medicinal composition and preparation method thereof | |
| CN101244068B (en) | Hemsleyadin sustained-release preparation | |
| CN101780094B (en) | Slow-release preparation of cucurbitacin | |
| CN101829121B (en) | Hemsleyadin sustained-release preparation | |
| CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| CN103505466B (en) | Solid compound preparation containing metformin hydrochloride and glimepiride and its production and use | |
| CN102293759A (en) | Dextral ibuprofen sustained release tablet preparation and preparation method thereof | |
| CN103007286A (en) | Solid medicine composition of tolvaptan | |
| CN1861056B (en) | Slow-releasing preparation containing gastrodin | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN103655585A (en) | Gastrodin controlled release preparation and preparation method thereof | |
| CN103371981A (en) | Compound repaglinide-metformin hydrochloride solid quick-release preparation and preparation method and application thereof | |
| CN107375938A (en) | A kind of adhesive of aminoglucose hydrochloride, tablet and preparation method thereof | |
| CN101890057A (en) | Herba Pteridis Multifidae preparation that treatment gastrointestinal tract, urinary tract infection and the heart, cerebrovascular disease are used and preparation method thereof | |
| CN105663063B (en) | Compound pellet tablet of diammonium glycyrrhizinate and Entecavir and preparation method thereof | |
| CN101185640B (en) | Lornoxicam sustained-release tablet and preparation method thereof | |
| CN115919867B (en) | Aidenafil citrate oral sustained-release preparation and preparation method and application thereof | |
| CN104013634A (en) | Capsule containing aspirin enteric part and dipyridamole quick-releasing part and preparation method thereof | |
| CN101129358B (en) | Moguisteine sustained-release tablet and method of preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: KUNMING XINGHAO SICHUANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SICHUANG PHARMACEUTICAL CO., LTD., KUNMING Owner name: KUNMING SICHUANG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: KUNMING XINGHAO SICHUANG PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 650106 No. 176, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee after: Kunming four Pharmaceutical Co.,Ltd. Address before: 650106 No. 176, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee before: KUNMING XINGHAO SICHUANG PHARMACEUTICAL Co.,Ltd. Address after: 650106 No. 176, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee after: KUNMING XINGHAO SICHUANG PHARMACEUTICAL Co.,Ltd. Address before: 650106 No. 176, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee before: Kunming Sichuang Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: KUNMING BENCAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: KUNMING SICHUANG PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 650106 No. 176, medical Road, Kunming hi tech Industrial Development Zone, Yunnan, China Patentee after: Kunming herb Pharmaceutical Co.,Ltd. Address before: 650106 No. 176, medical Road, hi tech Development Zone, Yunnan, Kunming Patentee before: Kunming four Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 650106 No. 176, medical Road, Kunming hi tech Industrial Development Zone, Yunnan, China Patentee after: Yunnan lanlokan Pharmaceutical Co.,Ltd. Address before: 650106 No. 176, medical Road, Kunming hi tech Industrial Development Zone, Yunnan, China Patentee before: Kunming herb Pharmaceutical Co.,Ltd. |